No in vitro synergistic effect of bedaquiline combined with fluoroquinolones, linezolid, and clofazimine against extensively drug-resistant tuberculosis
机构：[a]National Clinical Laboratory on Tuberculosis, Beijing Key laboratory for Drug Resistant Tuberculosis Research, Beijing Chest Hospital, CapitalMedical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China[b]Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China[c]Beijing Key Laboratory for Pediatric Diseases of Otolaryngology, Head and Neck Surgery, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China临床科室科研平台职能科室耳鼻咽喉头颈外科临床流行病与循证医学中心儿科研究所首都医科大学附属北京儿童医院
Purpose: We explored the potential synergistic effect of bedaquiline (BDQ) combined with moxifloxacin (MFX), gatifloxacin (GAT), clofazimine (CLO), and linezolid (LZD) for treatment of extensively drug-resistant tuberculosis (XDR-TB). Methods: Of 191 XDR-TB isolates, 20 exhibiting minimal inhibitory concentration (MIC) values >= 0.063 mu g/mL for BDQ were selected to study potential synergistic, additive, or antagonistic drug effects using a checkerboard assay. Results: Antagonism occurred in 14 (70.0%), 0 (0.0%), 13 (65.0%), and 4 (20.0%) XDR-TB isolates for BDQ-MFX, BDQ-GAT, BDQ-LZD, and BDQ-CLO combinations, respectively. Conclusion: Our in vitro data demonstrate no observed synergistic effects against XDR-TB for drug combinations that included BDQ in combination with MFX, GAT, LZD, or CLO. (C) 2019 Elsevier Inc. All rights reserved.
基金：
This study was supported by the Natural Science Foundation of
China (81301509) and the Capital’s Funds for Health Improvement
and Research (2016-4-1141). We are grateful to members of the
National Tuberculosis Clinical Laboratory at the Beijing Chest Hospital
for their cooperation and technical help.
第一作者机构：[a]National Clinical Laboratory on Tuberculosis, Beijing Key laboratory for Drug Resistant Tuberculosis Research, Beijing Chest Hospital, CapitalMedical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China
共同第一作者：
通讯作者：
通讯机构：[a]National Clinical Laboratory on Tuberculosis, Beijing Key laboratory for Drug Resistant Tuberculosis Research, Beijing Chest Hospital, CapitalMedical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China[b]Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China
推荐引用方式(GB/T 7714)：
Yu Pang,Wei Jing,Jie Lu,et al.No in vitro synergistic effect of bedaquiline combined with fluoroquinolones, linezolid, and clofazimine against extensively drug-resistant tuberculosis[J].DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE.2019,94(4):361-364.doi:10.1016/j.diagmicrobio.2019.02.012.
APA：
Yu Pang,Wei Jing,Jie Lu,Zhaojing Zong,Fengmin Huo...&Naihui Chu.(2019).No in vitro synergistic effect of bedaquiline combined with fluoroquinolones, linezolid, and clofazimine against extensively drug-resistant tuberculosis.DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE,94,(4)
MLA：
Yu Pang,et al."No in vitro synergistic effect of bedaquiline combined with fluoroquinolones, linezolid, and clofazimine against extensively drug-resistant tuberculosis".DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE 94..4(2019):361-364
